{
    "nct_id": "NCT03386526",
    "official_title": "A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as a Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies",
    "inclusion_criteria": "1. Histologically or cytologically confirmed solid tumor or hematological malignancies\n2. Life expectancy ≥ 3 months\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2\n4. Corrected QT interval (QTc) ≤ 450 ms in males, and ≤ 470 ms in females\n5. Adequate hematologic function\n6. International normalized ratio (INR), prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5 x upper limit of normal (ULN)\n7. Adequate renal and liver function\n8. Willingness to use contraception\n9. Ability to understand and willingness to sign a written informed consent form\n10. Willingness and ability to comply with study procedures and follow-up examination\n11. Have provided tissue for biomarker analysis from a newly or recently-obtained biopsy of a tumor lesion not previously irradiated\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior to entering the study\n2. Received hormonal, biologic (< 2 half-lives), small molecule targeted therapies or other anti-cancer therapy within 21 days of study entry\n3. Radiation or surgery within 14 days of study entry, thoracic radiation within 28 days of study entry\n4. Has known active central nervous (CNS) metastases and/or carcinomatous meningitis. Patients who have received prior radiotherapy for previous brain metastasis must have discontinued steroids for 14 days prior to study entry and be clinically stable\n5. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to ≤ Grade 1 except alopecia\n6. Requirement for corticosteroid treatment, with the exception of megestrol, local use of steroid\n7. Use of therapeutic anticoagulants\n8. International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≥ 1.5 x ULN\n9. Concurrent treatment with an investigational agent or device within 28 days prior to the first dose of therapy\n10. Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry\n11. Neurologic instability per clinical evaluation due to tumor involvement of the central nervous system (CNS)\n12. History of Bell's palsy\n13. Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation\n14. Active infection requiring systemic antibiotic/ antifungal medication\n15. Known or suspected Wilson's Disease\n16. Prior treatment with IAP inhibitors\n17. History of hypersensitivity to paclitaxel, or any therapeutic antibody\n18. Has an active autoimmune disease, or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents\n19. Is on chronic systemic steroid therapy\n20. Has received a live vaccine within 30 days prior to first dose\n21. Has had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant",
    "miscellaneous_criteria": ""
}